Annals of Internal Medicine (ACP) published a clinical update in Research Highlights on 03 Mar 2026. The item focuses on In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y. Review the original article for the full source wording and details.
Annals of Internal Medicine (ACP) published a clinical update in Research Highlights on 03 Mar 2026.
The item focuses on In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y.
Review the original article for the full source wording and details.